Fate Therapeutics Inc (FATE) financials
Fate Therapeutics revenue and earnings by year
Fate Therapeutics's revenue was $6.65 million in the fiscal year to December 31, 2025, down 51.2% from the year before. Net income was -$136 million, -2051.1% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 4.7% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7 | 14 | 64 | 96 | 56 | 31 | 11 | 5 | 4 | 4 |
| Revenue growth | -51.2% | -78.5% | -34.0% | 72.4% | 77.7% | 194.3% | 125.3% | 15.4% | -6.7% | — |
| Operating income | -148 | -210 | -191 | -308 | -217 | -128 | -101 | -67 | -42 | -32 |
| Operating margin | -2222.4% | -1542.6% | -299.9% | -320.2% | -388.6% | -407.5% | -943.1% | -1415.4% | -1025.9% | -726.1% |
| Net income | -136 | -186 | -161 | -282 | -212 | -173 | -98 | -67 | -43 | -33 |
| Net margin | -2051.1% | -1366.5% | -253.3% | -292.5% | -379.9% | -551.6% | -919.0% | -1405.0% | -1046.1% | -760.2% |
| Diluted EPS | -$1.15 | -$1.64 | -$1.64 | -$2.91 | -$2.23 | -$2.08 | -$1.44 | -$1.19 | -$1.01 | -$1.05 |
| Free cash flow | -112 | -124 | -138 | -284 | -214 | -44 | -91 | -41 | -39 | -30 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open FATE in Markets.
See also: FATE returns
No forecast, no recommendation. This page describes Fate Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.